• Myotonic Dystrophy Market Expected to Experience Accelerated openPR.com Wed, 08 Jul 2026 14:12:06 GMT
• if you invested $1,000 in design therapeutics, inc. (dsgn) Stock Titan Sat, 04 Jul 2026 05:05:01 GMT
• enterprise value to revenue forward of design therapeutics, inc. – nasdaq:dsgn TradingView Fri, 03 Jul 2026 06:31:52 GMT
• Price to sales forward of Design Therapeutics, Inc. – NASDAQ:DSGN TradingView Fri, 03 Jul 2026 05:05:58 GMT
• Cantor Fitzgerald reiterates Design Therapeutics stock rating Investing.com Wed, 01 Jul 2026 07:00:00 GMT
• design therapeutics initiates patient dosing in dt-818 trial TipRanks Tue, 30 Jun 2026 20:29:46 GMT
• Design Therapeutics stock rises on Phase 1 trial dosing start By Investing.com Investing.com Nigeria Tue, 30 Jun 2026 12:49:40 GMT
• Design Therapeutics begins dosing DM1 drug in phase 1 trial By Investing.com Investing.com South Africa Tue, 30 Jun 2026 12:42:46 GMT
• design therapeutics announces initiation of patient dosing in phase 1 multiple ascending dose trial of dt-818 for myotonic dystrop... The Manila Times Tue, 30 Jun 2026 12:04:18 GMT
• Design Therapeutics begins DM1 trial for DT-818, aims at genetic cause Stock Titan Tue, 30 Jun 2026 12:00:00 GMT
• Design Therapeutics, Inc.(NasdaqGS: DSGN) dropped from Russell 2000 Value Benchmark marketscreener.com Mon, 29 Jun 2026 15:30:51 GMT
• Design Therapeutics, Inc.(NasdaqGS:DSGN) dropped from Russell Microcap Value Benchmark Index marketscreener.com Mon, 29 Jun 2026 13:42:06 GMT
• Design Therapeutics, Inc.(NasdaqGS:DSGN) added to Russell Microcap Growth Benchmark Index marketscreener.com Mon, 29 Jun 2026 12:18:59 GMT
• Design Therapeutics, Inc.(NasdaqGS: DSGN) added to Russell 2000 Growth Benchmark marketscreener.com Mon, 29 Jun 2026 11:11:09 GMT
• We're Hopeful That Design Therapeutics (NASDAQ:DSGN) Will Use Its Cash Wisely simplywall.st Sat, 27 Jun 2026 07:00:00 GMT
• design therapeutics, inc. actuals & estimates (nasdaq:dsgn) TradingView Sat, 27 Jun 2026 05:22:18 GMT
• design therapeutics, inc. (dsgn) is up 6.92% in one week: what you should know MSN Thu, 25 Jun 2026 16:42:32 GMT
• design therapeutics stock wobbles after rare genetic disease data MSN Thu, 25 Jun 2026 05:03:48 GMT
• Design Therapeutics: FA Early Data And FDA Discussions Are Promising Catalysts Seeking Alpha Wed, 24 Jun 2026 07:00:00 GMT
• Design Therapeutics Inc (DSGN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution TradingKey Thu, 18 Jun 2026 00:57:31 GMT
• design therapeutics inc (dsgn) financial health: profitability & balance sheet analysis TradingKey Wed, 17 Jun 2026 18:54:01 GMT
• design therapeutics inc (dsgn) technical analysis: support, resistance, indicators & moving averages TradingKey Wed, 17 Jun 2026 18:48:56 GMT
• design therapeutics inc (dsgn) earnings forecast: future eps & revenue growth estimates TradingKey Wed, 17 Jun 2026 18:23:21 GMT
• design therapeutics inc (dsgn) risk assessment: volatility, financial risk & investment risk TradingKey Wed, 17 Jun 2026 18:23:01 GMT
• design therapeutics inc (dsgn) valuation: pe, pb & fair value analysis TradingKey Wed, 17 Jun 2026 18:18:53 GMT
• design therapeutics inc (dsgn) technical analysis: support, resistance, indicators & moving averages TradingKey Tue, 16 Jun 2026 07:00:00 GMT
• design therapeutics inc (dsgn) financial health: profitability & balance sheet analysis TradingKey Tue, 16 Jun 2026 07:00:00 GMT
• design therapeutics inc (dsgn) risk assessment: volatility, financial risk & investment risk TradingKey Tue, 16 Jun 2026 07:00:00 GMT
• design therapeutics (dsgn) gains 2.28% – approaching key resistance at $11.78 - weekly profile newsline.com Mon, 15 Jun 2026 16:38:23 GMT
• Oppenheimer Maintains Design Therapeutics(DSGN.US) With Buy Rating, Maintains Target Price $21 Moomoo Mon, 15 Jun 2026 07:00:00 GMT
• dsgn q1 2026 earnings: eps beat as net loss narrows - earnings expansion phase newsline.com Sun, 14 Jun 2026 05:34:48 GMT
• enliven therapeutics announces updated positive phase 1 clinical data and alignment with fda on key phase 3 trial design component... PR Newswire Thu, 11 Jun 2026 12:00:00 GMT
• Design Therapeutics (DSGN) grants George Simeon 30,000 stock options at $10.55 Stock Titan Thu, 11 Jun 2026 07:00:00 GMT
• director at design therapeutics (dsgn) awarded options on 30,000 shares Stock Titan Thu, 11 Jun 2026 07:00:00 GMT
• [form 4] design therapeutics, inc. insider trading activity Stock Titan Thu, 11 Jun 2026 07:00:00 GMT
• design therapeutics (dsgn) grants director david shapiro 30,000 options Stock Titan Thu, 11 Jun 2026 07:00:00 GMT
• design therapeutics (dsgn) director awarded 30,000 options at $10.55 strike Stock Titan Thu, 11 Jun 2026 07:00:00 GMT
• director at design therapeutics (dsgn) awarded 30,000 stock options Stock Titan Thu, 11 Jun 2026 07:00:00 GMT
• design therapeutics (nasdaq: dsgn) details outcomes of 2026 shareholder meeting votes Stock Titan Thu, 11 Jun 2026 07:00:00 GMT
• design therapeutics stockholders approve director and auditor at meeting TipRanks Thu, 11 Jun 2026 07:00:00 GMT
• dsgn q1 2026 earnings: narrower-than-expected loss highlights cost discipline - subscription growth report newsline.com Tue, 09 Jun 2026 21:34:43 GMT
• Point72-affiliated holders report 5.1% stake in Design Therapeutics (DSGN) Stock Titan Tue, 09 Jun 2026 07:00:00 GMT
• dsgn: early clinical data in friedreich's ataxia support rapid advancement to registrational studies TradingView Thu, 04 Jun 2026 18:35:47 GMT
• Waypoint Bio Raises $20M Series A Led by Amplify Partners to Advance AI-Designed Cell Therapies Toward the Clinic BioSpace Tue, 02 Jun 2026 07:00:00 GMT
• design therapeutics drops ahead of jefferies, trial remains in focus for dsgn Bez Kabli Tue, 02 Jun 2026 07:00:00 GMT
• design therapeutics (dsgn) slides 2.42% as biotech stock tests key support - iv crush alert newsline.com Sat, 30 May 2026 07:00:00 GMT
• design therapeutics (dsgn) dips as key support holds after 2.42% decline - naked poc The Legal Advocate Sat, 30 May 2026 00:43:44 GMT
• design therapeutics shares jump on encouraging friedreich ataxia trial results (dsgn) MSN Fri, 29 May 2026 18:28:06 GMT
• Capturing More of Earth’s Genomes to Advance Biological Breakthroughs the-scientist.com Fri, 29 May 2026 07:00:00 GMT
• design therapeutics (dsgn) dips as key support holds after 2.42% decline - wide range bar newsline.com Fri, 29 May 2026 07:00:00 GMT
• Piper Sandler Reaffirms Their Buy Rating on Design Therapeutics (DSGN) The Globe and Mail Thu, 28 May 2026 07:00:00 GMT
• Design Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference The Globe and Mail Thu, 28 May 2026 07:00:00 GMT
• Design Therapeutics (DSGN) Declines 2% as Shares Test Key Support Levels - Strong Buy Stocks dars.gov.et Thu, 28 May 2026 07:00:00 GMT
• biotech design therapeutics to join jefferies 2026 healthcare fireside chat Stock Titan Thu, 28 May 2026 07:00:00 GMT
• design therapeutics to present at 2026 jefferies global healthcare conference on june 4. Pluang Thu, 28 May 2026 07:00:00 GMT
• design therapeutics shares jump on encouraging friedreich ataxia trial results (dsgn) MSN Wed, 27 May 2026 09:06:29 GMT
• design therapeutics (dsgn) slips 0.57%, testing support zone amid light trading - point of control newsline.com Wed, 27 May 2026 07:00:00 GMT
• piper sandler maintains design therapeutics(dsgn.us) with buy rating, maintains target price $20 Moomoo Wed, 27 May 2026 07:00:00 GMT
• design therapeutics(dsgn) stock options chain | quotes & news Moomoo Wed, 27 May 2026 04:03:05 GMT
• design therapeutics shares jump on encouraging friedreich ataxia trial results (dsgn) MSN Tue, 26 May 2026 13:41:20 GMT
• design therapeutics (dsgn) consolidates near support after marginal decline - low volatility picks The Legal Advocate Mon, 25 May 2026 14:36:40 GMT
• design therapeutics shares jump on encouraging friedreich ataxia trial results (dsgn) MSN Sun, 24 May 2026 23:52:02 GMT
• design therapeutics shares jump on encouraging friedreich ataxia trial results (dsgn) MSN Sat, 23 May 2026 19:54:20 GMT
• design therapeutics (dsgn) holds steady near support as consolidation persists - value factor The Legal Advocate Sat, 23 May 2026 02:30:06 GMT
• design therapeutics (dsgn) price target increased by 17.05% to 17.51 MSN Fri, 22 May 2026 21:03:48 GMT
• design therapeutics (dsgn) edges higher as support holds above $10.60 - real trader network Newser Fri, 22 May 2026 16:33:18 GMT
• design therapeutics shares jump on encouraging friedreich ataxia trial results (dsgn) MSN Fri, 22 May 2026 14:36:02 GMT
• Design Therapeutics Inc. (DSGN) Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Progress in Gene Therapy Pipeline - High ... dars.gov.et Fri, 22 May 2026 07:00:00 GMT
• design therapeutics (dsgn) price target increased by 17.05% to 17.51 MSN Thu, 21 May 2026 22:39:51 GMT
• design therapeutics shares jump on encouraging friedreich ataxia trial results (dsgn) MSN Thu, 21 May 2026 15:23:03 GMT
• dt-216p2 shows dose-dependent frataxin increases and clinical improvements after 4 weeks of iv dosing in friedreich ataxia Neurology Live Wed, 20 May 2026 08:41:56 GMT
• blossomhill therapeutics expands board of directors with the appointments of sheila gujrathi, m.d., and john schmid The Manila Times Wed, 20 May 2026 07:00:00 GMT
• rbc capital maintains design therapeutics(dsgn.us) with buy rating, raises target price to $20 Moomoo Wed, 20 May 2026 02:31:00 GMT
• craig-hallum maintains design therapeutics(dsgn.us) with buy rating, raises target price to $22 Moomoo Tue, 19 May 2026 20:01:40 GMT
• design therapeutics shares jump on encouraging friedreich ataxia trial results (dsgn) MSN Tue, 19 May 2026 08:56:18 GMT
• design therapeutics stock wobbles after rare genetic disease data Sahm Tue, 19 May 2026 07:58:00 GMT
• Design Therapeutics reports Phase I/II RESTORE-FA trial outcomes Clinical Trials Arena Tue, 19 May 2026 07:00:00 GMT
• DT-216P2 Shows Dose-Dependent Frataxin Increases and Clinical Improvements After 4 Weeks of IV Dosing in Friedreich Ataxia NeurologyLive Tue, 19 May 2026 07:00:00 GMT
• Design Therapeutics, Inc. (DSGN) Discusses Data from RESTORE-FA Trial of DT-216P2 for Friedreich Ataxia - Slideshow (NASDAQ:DSGN) ... Seeking Alpha Tue, 19 May 2026 07:00:00 GMT
• dt-216p2 shows early signs of benefit in friedreich’s ataxia clinical trial Friedreich's Ataxia News Tue, 19 May 2026 07:00:00 GMT
• design therapeutics announces biomarker and clinical data from ongoing phase 1/2 restore-fa trial of dt-216p2 in friedreich ataxia... Minichart Tue, 19 May 2026 07:00:00 GMT
• design therapeutics announces biomarker and clinical data from ongoing phase 1/2 restore-fa trial of dt-216p2 in friedreich ataxia... Minichart Mon, 18 May 2026 16:54:00 GMT
• dsgn: dt-216p2 demonstrated strong biomarker and clinical improvements, supporting registrational plans TradingView Mon, 18 May 2026 14:05:26 GMT
• design therapeutics (dsgn) price target increased by 17.05% to 17.51 MSN Mon, 18 May 2026 10:50:33 GMT
• Design Therapeutics Shares Jump on Encouraging Friedreich Ataxia Trial Results (DSGN) Yahoo Finance Mon, 18 May 2026 07:00:00 GMT
• Four-week FA trial finds balance and fatigue gains with experimental drug Stock Titan Mon, 18 May 2026 07:00:00 GMT
• Design Therapeutics, Inc. Stock 12‑Month Price Target Raised to $20, Implies 39% Upside TradingView Mon, 18 May 2026 07:00:00 GMT
• RBC Capital raises Design Therapeutics price target on trial data Investing.com Mon, 18 May 2026 07:00:00 GMT
• Design Therapeutics Stock Wobbles After Rare Genetic Disease Data - Design Therapeutics (NASDAQ:DSGN) Benzinga Mon, 18 May 2026 07:00:00 GMT
• RESTORE-FA data push Design Therapeutics (DSGN) to plan registrational path Stock Titan Mon, 18 May 2026 07:00:00 GMT
• This Biotech Leader Ran Up As Much As 18% — And Then Lost It All Investor's Business Daily Mon, 18 May 2026 07:00:00 GMT
• Design Therapeutics’ Friedreich’s ataxia data; Vincentage’s obesity results from China Endpoints News Mon, 18 May 2026 07:00:00 GMT
• Design Therapeutics reports positive RESTORE-FA trial data | DSGN grafa.com Mon, 18 May 2026 07:00:00 GMT
• Design Therapeutics reports positive trial data for FA treatment By Investing.com Investing.com Nigeria Mon, 18 May 2026 07:00:00 GMT
• Design Therapeutics' DT-216P2 Shows Clinical Improvements in Friedreich Ataxia Trial; Shares Rise Pre-Bell marketscreener.com Mon, 18 May 2026 07:00:00 GMT
• Design Therapeutics to Host Investor Webcast to Review Data from RESTORE-FA Trial of DT-216P2 for Friedreich’s Ataxia on Monday, M... The Manila Times Mon, 18 May 2026 07:00:00 GMT
• Design Therapeutics stock surges on positive trial data Investing.com Mon, 18 May 2026 07:00:00 GMT
• Crude Oil Gains Over 2%; US Homebuilder Sentiment Increases In May - Design Therapeutics (NASDAQ:DSGN), F Benzinga Mon, 18 May 2026 07:00:00 GMT
• Design Therapeutics reports positive Phase 1/2 DT-216P2 data TipRanks Mon, 18 May 2026 07:00:00 GMT
• larimar therapeutics: buy rating backed by superior nomlabofusp data and favorable risk-reward versus design therapeutics TipRanks Mon, 18 May 2026 07:00:00 GMT
• design therapeutics announces four-week iv data from the restore-fa trial of dt-216p2 demonstrating clinical improvements and comp... TradingView Mon, 18 May 2026 07:00:00 GMT
• design therapeutics reports phase 1/2 trial data for dt-216p2 in friedreich ataxia Investing.com Mon, 18 May 2026 07:00:00 GMT
• jim cramer flags design therapeutics as ‘pure spec’ – what investors should know - positive surprise momentum newsline.com Mon, 18 May 2026 07:00:00 GMT
• design therapeutics down over 25%, on track for largest percent decrease since august 2023 -- data talk Moomoo Mon, 18 May 2026 07:00:00 GMT
• jim cramer labels design therapeutics a 'pure speculative play' – what investors should know - surprise factor analysis The Legal Advocate Mon, 18 May 2026 07:00:00 GMT
• jim cramer calls design therapeutics ‘pure spec’ — what it means for biotech speculation - earnings expansion phase The Legal Advocate Mon, 18 May 2026 07:00:00 GMT
• design therapeutics announces biomarker, clinical data from restore-fa trial TipRanks Mon, 18 May 2026 07:00:00 GMT
• jim cramer: design therapeutics is 'pure spec,' buy this health care stock MSN Mon, 18 May 2026 06:02:45 GMT
• design therapeutics to host investor webcast to review data from restore-fa trial of dt-216p2 ... Caledonian Record Sun, 17 May 2026 20:02:14 GMT
• Design Therapeutics to Announce Phase 1/2 RESTORE-FA Trial Data for DT-216P2 in Friedreich's Ataxia on May 18, 2026 Quiver Quantitative Sun, 17 May 2026 07:00:00 GMT
• Jim Cramer on Design Therapeutics: “Pure Spec, Pure Spec” Yahoo Finance Sun, 17 May 2026 07:00:00 GMT
• Friedreich’s ataxia trial data to be unveiled in May 18 webcast Stock Titan Sun, 17 May 2026 07:00:00 GMT
• design therapeutics to present phase 1/2 trial data for friedreich’s ataxia drug dt-216p2 on may 18 Pluang Sun, 17 May 2026 07:00:00 GMT
• design therapeutics (dsgn) price target increased by 17.05% to 17.51 MSN Sat, 16 May 2026 08:44:24 GMT
• jim cramer: design therapeutics is 'pure spec,' buy this health care stock MSN Sat, 16 May 2026 04:36:42 GMT
• Cramer: Design Therapeutics Is ‘Pure Spec,’ Buy This Health Care Stock - BillionToOne (NASDAQ:BLLN), Desi Benzinga Fri, 15 May 2026 07:00:00 GMT
• jim cramer: design therapeutics is 'pure spec,' buy this health care stock Benzinga Fri, 15 May 2026 07:00:00 GMT
• point72 (dsgn) discloses 2.72m-share stake, 4.4% ownership Stock Titan Fri, 15 May 2026 07:00:00 GMT
• dyne therapeutics to participate in upcoming investor conferences Yahoo Finance Wed, 13 May 2026 07:00:00 GMT
• design therapeutics initiated with an overweight at cantor fitzgerald TipRanks Wed, 13 May 2026 00:47:37 GMT
• design therapeutics initiated with an overweight at cantor fitzgerald TipRanks Tue, 12 May 2026 13:42:03 GMT
• Form Bio Launches FormManufacturing, an End-to-End Platform for AI-Driven Design and Manufacturing of Genetic Medicines Newswire.com Mon, 11 May 2026 07:00:00 GMT
• design therapeutics, inc. (dsgn) is up 6.92% in one week: what you should know Yahoo Finance Mon, 11 May 2026 07:00:00 GMT
• entrada’s stock drops as dmd drug’s efficacy falls short Clinical Trials Arena Fri, 08 May 2026 07:00:00 GMT
• oppenheimer maintains design therapeutics(dsgn.us) with buy rating, raises target price to $21 富途牛牛 Wed, 06 May 2026 11:16:12 GMT
• dsgn sec filings - design therapeutics, inc. 10-k, 10-q, 8-k forms Stock Titan Tue, 05 May 2026 05:15:37 GMT
• design therapeutics price target raised to $21 from $18 at oppenheimer TipRanks Mon, 04 May 2026 13:52:22 GMT
• oppenheimer raises price target on design therapeutics to $21 from $18, keeps outperform rating marketscreener.com Mon, 04 May 2026 13:41:23 GMT
• oppenheimer maintains design therapeutics(dsgn.us) with buy rating, raises target price to $21 Moomoo Mon, 04 May 2026 12:35:01 GMT
• design therapeutics set for multiple clinical trial catalysts in h2 2026 RTTNews Mon, 04 May 2026 07:00:00 GMT
• design therapeutics, inc. (nasdaq:dsgn) receives consensus rating of "moderate buy" from analysts MarketBeat Sun, 03 May 2026 10:23:22 GMT
• design therapeutics (dsgn) price target increased by 12.82% to 14.96 MSN Sat, 02 May 2026 12:32:03 GMT
Design Therapeutics, Inc(NASDAQ:DSGN) 
Design Therapeutics, Inc. develops therapies for the treatment of degenerative disorders caused by nucleotide repeat expansions. The company engages in the development of a program for the treatment of Friedreich's ataxia and degenerative diseases such as Fragile X syndrome and myotonic dystrophy. T...
Share this website to your friends